Autolus announces pricing of public offering

11th April 2019

LONDON, 11 April, 2019: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company Autolus Therapeutics plc (Nasdaq: AUTL) (“Autolus”), today announced the pricing of its previously announced underwritten public offering in the United States of 4,200,000 American Depositary Shares (“ADSs”) representing 4,200,000 ordinary shares, at a public offering price of $24.00 per ADS, for total gross proceeds of approximately $100.8 million (£77.0 million[1]). All ADSs sold in the offering were offered by Autolus.

Arix has agreed to invest $5.0 million (£3.8 million1) in the offering. Following the offering, Arix retains a stake of 7.6% in Autolus (amounting to 3,369,868 ordinary shares, including ordinary shares in the form of ADSs), which was valued at £62.6 million at close of business on 10 April 2019.

"Our investment in Autolus today demonstrates our strategy to build world leading biotech companies through the provision of flexible, long term capital. We believe Autolus is at the forefront of a revolution in cancer treatment and that its innovative approach to T-cell programming has the potential to offer life-changing therapies for patients.”

Joe Anderson, Chief Executive Officer of Arix and Autolus Board Member

This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

The securities referred to in this announcement are to be offered only by means of a prospectus. When available, copies of the prospectus can be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at +1 866 471 2526 or by email at prospectusgroup-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at +1 877 821 7388 or by email at Prospectus_Department@Jefferies.com. For the avoidance of doubt, such prospectus will not constitute a "prospectus" for the purposes of Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each relevant EU member state) and will not have been reviewed by any competent authority in any EU member state.

A registration statement on Form F-1 (File No. 333-230767) relating to the ADSs being sold in this offering was declared effective by the U.S. Securities and Exchange Commission on 10 April 2019.

[1] At exchange rate on 10 April 2019